Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Phone801-584-3600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$851.10 million
Profitability
Miscellaneous
Employees2,600
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions
What is Myriad Genetics' stock symbol?
Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."
How were Myriad Genetics' earnings last quarter?
Myriad Genetics, Inc. (NASDAQ:MYGN) issued its quarterly earnings data on Tuesday, August, 13th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.40 by $0.01. The firm earned $215.40 million during the quarter, compared to the consensus estimate of $221.64 million. Myriad Genetics had a return on equity of 9.09% and a net margin of 0.54%. The company's quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the company earned $0.38 EPS. View Myriad Genetics' Earnings History.
When is Myriad Genetics' next earnings date?
What guidance has Myriad Genetics issued on next quarter's earnings?
Myriad Genetics updated its FY20 earnings guidance on Tuesday, August, 13th. The company provided earnings per share (EPS) guidance of $1.80-1.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.94. The company issued revenue guidance of $865-875 million, compared to the consensus revenue estimate of $920.73 million.
What price target have analysts set for MYGN?
7 brokerages have issued 1-year target prices for Myriad Genetics' stock. Their predictions range from $22.00 to $40.00. On average, they anticipate Myriad Genetics' stock price to reach $30.91 in the next year. This suggests a possible upside of 1.1% from the stock's current price. View Analyst Price Targets for Myriad Genetics.
What is the consensus analysts' recommendation for Myriad Genetics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 2 sell ratings and 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myriad Genetics.
Has Myriad Genetics been receiving favorable news coverage?
Media headlines about MYGN stock have been trending somewhat positive on Sunday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myriad Genetics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Myriad Genetics.
Are investors shorting Myriad Genetics?
Myriad Genetics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 11,910,000 shares, an increase of 14.2% from the August 30th total of 10,430,000 shares. Based on an average trading volume of 1,400,000 shares, the days-to-cover ratio is presently 8.5 days. Approximately 16.6% of the company's shares are short sold. View Myriad Genetics' Current Options Chain.
Who are some of Myriad Genetics' key competitors?
Some companies that are related to Myriad Genetics include IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Lantheus (LNTH), Heska (HSKA), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), ImmuCell (ICCC) and Celldex Therapeutics (CLDX).
What other stocks do shareholders of Myriad Genetics own?
Who are Myriad Genetics' key executives?
Myriad Genetics' management team includes the folowing people:
- Mr. Mark Christopher Capone, CEO, Pres & Director (Age 57)
- Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 48)
- Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 60)
- Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 61)
- Mr. Alexander Ford, Pres of Myriad Women's Health (Age 52)
Who are Myriad Genetics' major shareholders?
Myriad Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.08%), Ingalls & Snyder LLC (0.06%), Stephens Inc. AR (0.06%), Envestnet Asset Management Inc. (0.03%), CHICAGO TRUST Co NA (0.01%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Myriad Genetics stock include Alexander Ford, Bernard Tobin, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.
Which institutional investors are selling Myriad Genetics stock?
MYGN stock was sold by a variety of institutional investors in the last quarter, including Stephens Inc. AR and Ingalls & Snyder LLC. Company insiders that have sold Myriad Genetics company stock in the last year include Bernard Tobin, Gary A King, Ralph L Mcdade and Richard Bryan Riggsbee. View Insider Buying and Selling for Myriad Genetics.
Which institutional investors are buying Myriad Genetics stock?
MYGN stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Envestnet Asset Management Inc., Nisa Investment Advisors LLC, CHICAGO TRUST Co NA and Meeder Asset Management Inc.. View Insider Buying and Selling for Myriad Genetics.
How do I buy shares of Myriad Genetics?
Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Myriad Genetics' stock price today?
One share of MYGN stock can currently be purchased for approximately $30.57.
How big of a company is Myriad Genetics?
Myriad Genetics has a market capitalization of $2.27 billion and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe.View Additional Information About Myriad Genetics.
What is Myriad Genetics' official website?
How can I contact Myriad Genetics?
Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]
MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
